Achaogen (AKAO) PT Raised to $25 at William Blair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Achaogen (AKAO) Sees Red-to-Green Reversal
December 14, 2016 9:46 AM ESTAchaogen (NASDAQ: AKAO) sees strong red-to-green reversal after pricing its equity offering at $13.50. Shares were last up 0.5% to $14.94.
Shares have surged over the past two session amid positive trial data.
... MoreAchaogen (AKAO) Consolidates Gains Ahead of Equity Pricing
December 13, 2016 3:35 PM ESTAchaogen (NASDAQ: AKAO) is giving some daily gains back into the close and ahead of the pricing of its common stock offering. Last up 13% to $14.72. The company is selling 5.75M shares.
... MoreAchaogen (AKAO) Bucks Stock Offering Weakness Amid Bullish Analyst Predictions
December 13, 2016 8:45 AM ESTAfter gaining 148% on Monday amid positive trial results, Achaogen (NASDAQ: AKAO) is up another 13% in pre-open trade Tuesday despite announcing a public offering of up to 5,750,000 shares of its common stock.
The stock appears to be keying off an... More
Needham & Company Upgrades Achaogen (AKAO) to Buy
December 12, 2016 4:15 PM ESTNeedham & Company upgraded Achaogen (NASDAQ: AKAO) from Hold to Buy with a price target of $19.00.
Analyst Alan Carr commented, "Achaogen announced surprisingly positive results from both Phase 3 trials of plazomicin in CRE infections (CARE trial) and complicated Urinary Tract Infections (EPIC trial). Given small size of... More
Achaogen (AKAO) Commences 5.75M Offering of Common Stock
December 12, 2016 4:03 PM ESTAchaogen, Inc. (NASDAQ: AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to 5,750,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market... More
Achaogen's (AKAO) Phase 3 cUTI and CRE Trial of Plazomicin Achieves Primary Endpoints
December 12, 2016 7:03 AM ESTAchaogen, Inc. (NASDAQ: AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that its lead product candidate, plazomicin, met the objective of non-inferiority compared to meropenem for the U.S. Food and Drug Administration (FDA) and achieved superiority for the European Medicines Agency (EMA) primary efficacy endpoints in the Phase 3 EPIC registration trial in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In addition, in the Phase 3 CARE trial in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) a lower rate of mortality or serious... More
